Increasing cases of menstrual cramps due to genetic disorders are expected to boost the growth of the global dysmenorrhea treatment market at a CAGR of 8.2% during the forecast period of 2023 to 2032.

Market Research Future (MRFR) has published a cooked research report on the “Global Dysmenorrhea Treatment Market” that contains information from 2018 to 2030. The Global Dysmenorrhea Treatment Market is estimated to register a CAGR of 8.2% during the forecast period of 2023 to 2030.

MRFR recognizes the following companies as the key players in the Global Dysmenorrhea Treatment Market  — Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Focus Consumer, Healthcare LLC (US), Novartis AG (Switzerland), Pfizer Inc. (US), Reckitt Benckiser Group plc. (UK), Sanofi S.A. (France)

Global Dysmenorrhea Treatment Market Highlights

The Global Dysmenorrhea Treatment Market is accounted to register a CAGR of 8.2% during the forecast period and is estimated to reach USD 7.69 billion by 2032.

Dysmenorrhea refers to the medical condition characterized by painful menstrual periods. It is a common condition experienced by many women during their reproductive years. The global dysmenorrhea treatment market includes various products and therapies aimed at managing and alleviating the symptoms associated with this condition. These treatments can be categorized into pharmaceuticals, devices, and alternative therapies.

Segment Analysis

The Global Dysmenorrhea Treatment Market has been segmented based Product Type, Type of treatment, and End-user.

The market segmentation of dysmenorrhea treatment, based on product type, includes primary dysmenorrhea, and secondary dysmenorrhea treatment. The primary dysmenorrhea treatment segment held the majority share in 2022 contributing to around ~65-67% in respect to the dysmenorrhea treatment market revenue. This is due to the increasing prevalence of primary dysmenorrhea and the rising awareness about the effective treatment options available.

The dysmenorrhea treatment market segmentation, based on type of treatment, includes pain relievers, hormonal therapy, and surgery. The pain reliever segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2023-2032. This is due to the widespread availability, low cost, and high therapeutic effect of non-steroidal anti-inflammatory drugs (NSAIDs) are driving the popularity of pain relievers and increasing their market share. NSAIDs are the most commonly used drugs for treating dysmenorrhea and are widely available in pharmacies and drug stores.

The market of dysmenorrhea treatment data has been bifurcated by end users into hospitals & clinics and research centers. The hospitals and clinic segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2023-2032.

Regional Analysis

The Global Dysmenorrhea Treatment Market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Dysmenorrhea Treatment market accounted for USD 1.603 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. North America is expected to be a significant contributor to the market for dysmenorrhea treatment, with the US being a major contributor. This is due to the high incidence and prevalence of dysmenorrhea and increased awareness of the condition among women, with 31.31 million women in the US reporting menstrual/period pain in 2020. The launch of new products for treating dysmenorrhea and the approval of new drugs by the FDA are also driving the market's growth in North America.

Europe dysmenorrhea treatment market accounts for the second-largest market share. The increasing prevalence of dysmenorrhea, along with the growing awareness and increasing number of R&D activities in Europe, is expected to drive the market growth of the dysmenorrhea treatment in the region. With a projected market share of 24% by 2022, Europe is expected to be one of the fastest-growing markets for dysmenorrhea treatment during the forecast period 2023-2030. Moreover, UK dysmenorrhea treatment held the largest market share, and the German dysmenorrhea treatment was the fastest-growing market in the region.

Asia Pacific market of dysmenorrhea treatment is expected to grow at the fastest CAGR from 2022 to 2030. The increasing awareness about menstrual health and the need for better treatment options is driving the growth of the Asia Pacific market for women's wellness technology. Additionally, the growth of healthcare infrastructure and government initiatives in the region are expected to further fuel dysmenorrhea treatment market growth. Further, the China dysmenorrhea treatment held the largest market share, and the Indian dysmenorrhea treatment was the fastest-growing market in the region.

Key Findings of the Study

• The Global Dysmenorrhea Treatment Market is expected to reach USD 7.69 billion by 2032, at a CAGR of 8.2% during the forecast period.


• Asia Pacific market of dysmenorrhea treatment is expected to grow at the fastest CAGR from 2022 to 2030. The increasing awareness about menstrual health and the need for better treatment options is driving the growth of the Asia Pacific market for women's wellness technology.


• The market segmentation of dysmenorrhea treatment, based on product type, includes primary dysmenorrhea, and secondary dysmenorrhea treatment.


• Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Focus Consumer, Healthcare LLC (US), Novartis AG (Switzerland), Pfizer Inc. (US), Reckitt Benckiser Group plc. (UK), Sanofi S.A. (France) 

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Dysmenorrhea Treatment Market Research Report